BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

604 related articles for article (PubMed ID: 16397241)

  • 1. Somatic mutations lead to an oncogenic deletion of met in lung cancer.
    Kong-Beltran M; Seshagiri S; Zha J; Zhu W; Bhawe K; Mendoza N; Holcomb T; Pujara K; Stinson J; Fu L; Severin C; Rangell L; Schwall R; Amler L; Wickramasinghe D; Yauch R
    Cancer Res; 2006 Jan; 66(1):283-9. PubMed ID: 16397241
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Activation of MET by gene amplification or by splice mutations deleting the juxtamembrane domain in primary resected lung cancers.
    Onozato R; Kosaka T; Kuwano H; Sekido Y; Yatabe Y; Mitsudomi T
    J Thorac Oncol; 2009 Jan; 4(1):5-11. PubMed ID: 19096300
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Met gene copy number predicts the prognosis for completely resected non-small cell lung cancer.
    Okuda K; Sasaki H; Yukiue H; Yano M; Fujii Y
    Cancer Sci; 2008 Nov; 99(11):2280-5. PubMed ID: 19037978
    [TBL] [Abstract][Full Text] [Related]  

  • 4. c-MET mutational analysis in small cell lung cancer: novel juxtamembrane domain mutations regulating cytoskeletal functions.
    Ma PC; Kijima T; Maulik G; Fox EA; Sattler M; Griffin JD; Johnson BE; Salgia R
    Cancer Res; 2003 Oct; 63(19):6272-81. PubMed ID: 14559814
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Epidermal growth factor receptors harboring kinase domain mutations associate with the heat shock protein 90 chaperone and are destabilized following exposure to geldanamycins.
    Shimamura T; Lowell AM; Engelman JA; Shapiro GI
    Cancer Res; 2005 Jul; 65(14):6401-8. PubMed ID: 16024644
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The C-terminus of Hsp70-interacting protein promotes Met receptor degradation.
    Jang KW; Lee JE; Kim SY; Kang MW; Na MH; Lee CS; Song KS; Lim SP
    J Thorac Oncol; 2011 Apr; 6(4):679-87. PubMed ID: 21325980
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Lung cancer cell lines harboring MET gene amplification are dependent on Met for growth and survival.
    Lutterbach B; Zeng Q; Davis LJ; Hatch H; Hang G; Kohl NE; Gibbs JB; Pan BS
    Cancer Res; 2007 Mar; 67(5):2081-8. PubMed ID: 17332337
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Met/Hepatocyte growth factor receptor ubiquitination suppresses transformation and is required for Hrs phosphorylation.
    Abella JV; Peschard P; Naujokas MA; Lin T; Saucier C; Urbé S; Park M
    Mol Cell Biol; 2005 Nov; 25(21):9632-45. PubMed ID: 16227611
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Defective ubiquitinylation of EGFR mutants of lung cancer confers prolonged signaling.
    Shtiegman K; Kochupurakkal BS; Zwang Y; Pines G; Starr A; Vexler A; Citri A; Katz M; Lavi S; Ben-Basat Y; Benjamin S; Corso S; Gan J; Yosef RB; Giordano S; Yarden Y
    Oncogene; 2007 Oct; 26(49):6968-78. PubMed ID: 17486068
    [TBL] [Abstract][Full Text] [Related]  

  • 10. RNA interference reveals that ligand-independent met activity is required for tumor cell signaling and survival.
    Shinomiya N; Gao CF; Xie Q; Gustafson M; Waters DJ; Zhang YW; Vande Woude GF
    Cancer Res; 2004 Nov; 64(21):7962-70. PubMed ID: 15520203
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Ror1 is a pseudokinase that is crucial for Met-driven tumorigenesis.
    Gentile A; Lazzari L; Benvenuti S; Trusolino L; Comoglio PM
    Cancer Res; 2011 Apr; 71(8):3132-41. PubMed ID: 21487037
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Differential responsiveness of MET inhibition in non-small-cell lung cancer with altered CBL.
    Tan YC; Mirzapoiazova T; Won BM; Zhu L; Srivastava MK; Vokes EE; Husain AN; Batra SK; Sharma S; Salgia R
    Sci Rep; 2017 Aug; 7(1):9192. PubMed ID: 28835699
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Induction of MET by ionizing radiation and its role in radioresistance and invasive growth of cancer.
    De Bacco F; Luraghi P; Medico E; Reato G; Girolami F; Perera T; Gabriele P; Comoglio PM; Boccaccio C
    J Natl Cancer Inst; 2011 Apr; 103(8):645-61. PubMed ID: 21464397
    [TBL] [Abstract][Full Text] [Related]  

  • 14. MET gene amplification or EGFR mutation activate MET in lung cancers untreated with EGFR tyrosine kinase inhibitors.
    Kubo T; Yamamoto H; Lockwood WW; Valencia I; Soh J; Peyton M; Jida M; Otani H; Fujii T; Ouchida M; Takigawa N; Kiura K; Shimizu K; Date H; Minna JD; Varella-Garcia M; Lam WL; Gazdar AF; Toyooka S
    Int J Cancer; 2009 Apr; 124(8):1778-84. PubMed ID: 19117057
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Epidermal growth factor receptors with tyrosine kinase domain mutations exhibit reduced Cbl association, poor ubiquitylation, and down-regulation but are efficiently internalized.
    Padrón D; Sato M; Shay JW; Gazdar AF; Minna JD; Roth MG
    Cancer Res; 2007 Aug; 67(16):7695-702. PubMed ID: 17699773
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A conserved DpYR motif in the juxtamembrane domain of the Met receptor family forms an atypical c-Cbl/Cbl-b tyrosine kinase binding domain binding site required for suppression of oncogenic activation.
    Peschard P; Ishiyama N; Lin T; Lipkowitz S; Park M
    J Biol Chem; 2004 Jul; 279(28):29565-71. PubMed ID: 15123609
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Hepatocyte growth factor induces gefitinib resistance of lung adenocarcinoma with epidermal growth factor receptor-activating mutations.
    Yano S; Wang W; Li Q; Matsumoto K; Sakurama H; Nakamura T; Ogino H; Kakiuchi S; Hanibuchi M; Nishioka Y; Uehara H; Mitsudomi T; Yatabe Y; Nakamura T; Sone S
    Cancer Res; 2008 Nov; 68(22):9479-87. PubMed ID: 19010923
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Distinct recruitment of Eps15 via Its coiled-coil domain is required for efficient down-regulation of the met receptor tyrosine kinase.
    Parachoniak CA; Park M
    J Biol Chem; 2009 Mar; 284(13):8382-94. PubMed ID: 19109251
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Gefitinib-sensitizing EGFR mutations in lung cancer activate anti-apoptotic pathways.
    Sordella R; Bell DW; Haber DA; Settleman J
    Science; 2004 Aug; 305(5687):1163-7. PubMed ID: 15284455
    [TBL] [Abstract][Full Text] [Related]  

  • 20. MET gene copy number in non-small cell lung cancer: molecular analysis in a targeted tyrosine kinase inhibitor naïve cohort.
    Beau-Faller M; Ruppert AM; Voegeli AC; Neuville A; Meyer N; Guerin E; Legrain M; Mennecier B; Wihlm JM; Massard G; Quoix E; Oudet P; Gaub MP
    J Thorac Oncol; 2008 Apr; 3(4):331-9. PubMed ID: 18379349
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 31.